Dupilumab is named as an intervention in 31 current clinical trials in our USA, China, UK, Ireland and India registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sanofi (11). The most-studied condition is Atopic Dermatitis.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
5 single-substance products containing Dupilumab on the HPRA medicines list.
No entry for Dupilumab in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Atopic Dermatitis | 8 |
| Asthma | 3 |
| Prurigo Nodularis | 2 |
| Healthy Volunteers | 2 |
| Chronic Obstructive Pulmonary Disease | 1 |
| Dermatitis Atopic | 1 |
| Wheezing | 1 |
| Chronic Spontaneous Urticaria (CSU) | 1 |
| Eosinophilic Gastritis (EoG) | 1 |
| Eosinophilic Duodenitis (EoD) | 1 |
| Eosinophilic Gastrointestinal Disease (EGID) | 1 |
| Eosinophilic Gastroenteritis | 1 |
| Eosinophilic Esophagitis (EoE) | 1 |
| Eosinophilic Oesophagitis | 1 |
| Colitis Ulcerative | 1 |
| Pruritus | 1 |
| COPD (Chronic Obstructive Pulmonary Disease) | 1 |
| Adverse Pregnancy Outcomes | 1 |
| Food Allergy | 1 |
| Chronic Rhinosinusitis With Nasal Polyposis | 1 |
| Dermatitis, Atopic | 1 |
| Healthy Participants | 1 |
| Asthma in Children | 1 |
| Biosimilarity | 1 |
| Atopic Dermatitis (AD) | 1 |
| Lead sponsor | Trials |
|---|---|
| Sanofi | 11 |
| Regeneron Pharmaceuticals | 8 |
| Innovent Biologics (Suzhou) Co. Ltd. | 4 |
| AbbVie | 2 |
| Novartis Pharmaceuticals | 1 |
| Pfizer | 1 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 1 |
| Guangzhou Institute of Respiratory Disease | 1 |
| Gan & Lee Pharmaceuticals. | 1 |
| Jiangsu Genscend Biopharmaceutical Co., Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 23 | 9 |
| Clinical trials in China | 13 | 5 |
| Clinical trials in UK | 6 | 2 |
| Clinical trials in Ireland | 1 | 0 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
31 current trials in our USA, China, UK, Ireland and India registers name Dupilumab (also registered as REGN668) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 31 trials are recruiting: 9 with sites in USA, 5 with sites in China and 2 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sanofi (11), Regeneron Pharmaceuticals (8), Innovent Biologics (Suzhou) Co. Ltd (4) and AbbVie (2), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 5 single-substance products containing Dupilumab, for example Dupixent (Sanofi Winthrop Industrie). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Dupilumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dupilumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dupilumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dupilumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.